GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Satellos Bioscience Inc (TSX:MSCL) » Definitions » ROIC %

Satellos Bioscience (TSX:MSCL) ROIC % : -628.41% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Satellos Bioscience ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Satellos Bioscience's annualized return on invested capital (ROIC %) for the quarter that ended in Dec. 2023 was -628.41%.

As of today (2024-05-12), Satellos Bioscience's WACC % is 9.41%. Satellos Bioscience's ROIC % is -381.31% (calculated using TTM income statement data). Satellos Bioscience earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Satellos Bioscience ROIC % Historical Data

The historical data trend for Satellos Bioscience's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Satellos Bioscience ROIC % Chart

Satellos Bioscience Annual Data
Trend Dec20 Dec21 Dec22 Dec23
ROIC %
-772.25 -128.20 -151.79 -389.40

Satellos Bioscience Quarterly Data
Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -167.37 -162.27 -292.82 -441.68 -628.41

Competitive Comparison of Satellos Bioscience's ROIC %

For the Biotechnology subindustry, Satellos Bioscience's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Satellos Bioscience's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Satellos Bioscience's ROIC % distribution charts can be found below:

* The bar in red indicates where Satellos Bioscience's ROIC % falls into.



Satellos Bioscience ROIC % Calculation

Satellos Bioscience's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=-15.463 * ( 1 - 0% )/( (3.966 + 3.976)/ 2 )
=-15.463/3.971
=-389.40 %

where

Satellos Bioscience's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Dec. 2023 is calculated as:

ROIC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-24.992 * ( 1 - 0% )/( (3.978 + 3.976)/ 2 )
=-24.992/3.977
=-628.41 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Satellos Bioscience  (TSX:MSCL) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Satellos Bioscience's WACC % is 9.41%. Satellos Bioscience's ROIC % is -381.31% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Satellos Bioscience ROIC % Related Terms

Thank you for viewing the detailed overview of Satellos Bioscience's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Satellos Bioscience (TSX:MSCL) Business Description

Traded in Other Exchanges
Address
65 Front Street East, Suite 201, Toronto, ON, CAN, M5E 1B5
Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation which Satellos has identified as a root cause of the progressive nature of this disease.

Satellos Bioscience (TSX:MSCL) Headlines

No Headlines